Lux Capital

Lux Capital backs frontier science and technology across sectors such as aerospace, biotechnology, defense and national security, industrial automation, transportation, data & AI, sensing, and related deep‑tech domains. Their core belief is turning "sci‑fi into sci‑fact" by partnering with founders who have rare technical expertise and are tackling problems where compute, automation, or biology can generate asymmetrical advantages. Lux is stage‑agnostic, deploying checks from $100 K up to $100 M and staying invested from the earliest experiments through large growth rounds. Geographically, the firm is global, anchored in New York with a Silicon Valley office, and it invests in companies worldwide. While it does not publish a formal anti‑thesis, Lux avoids overly crowded, incremental markets lacking a hard technical edge, focusing instead on non‑consensus categories where markets are misunderstood or nascent. This thesis drives a long‑term partnership model that treats capital as a tool to scale breakthrough science into enduring businesses.

Lux invests when a startup demonstrates a deep technical moat and is led by founders with rare domain expertise—often PhDs or seasoned engineers—pursuing hard problems where compute, automation, or biology create asymmetry. The firm favors non‑consensus theses and technologies that could become critical infrastructure, such as national‑security AI platforms or novel therapeutics. In evaluating deals, Lux places the team and technology above early market traction; at seed stage it will back pre‑product, pre‑revenue companies based on scientific merit, while later stages require clear productization, strategic contracts, or milestone achievements. Deal‑breakers include incremental offerings lacking a hard technical edge, overly crowded markets, and weak founder‑market fit in highly technical domains.

• Hugging FaceLead
  Open–source NLP platform core to the AI ecosystem, matching Lux’s AI/infra frontier thesis.
• MatterportLead
  3D capture of the built world combines computer vision and hardware at scale, fitting Lux’s deep–tech focus.
• Auris HealthLead
  Transformational surgical–robotics company at the intersection of AI and biotech, aligned with Lux’s health–tech frontier agenda.
• HadrianLead
  Autonomous, software–defined factories for precision defense/space components, exemplifying Lux’s industrial–automation thesis.
• Applied IntuitionLead
  Vehicle–intelligence and autonomy tooling that brings AI software into large–scale automotive and aerospace markets.
• OsmoLead
  AI–powered fragrance design merges machine learning with chemistry, a novel frontier application of AI.
• KallyopeLead
  Platform biotech unlocking the gut–brain axis, reflecting Lux’s science–driven biotech investments.
• Benchling
  Life–sciences R&D cloud provides data infrastructure for biotech, fitting Lux’s health–tech interest.
• Runway
  Next–gen creative AI tools align with Lux’s support for frontier AI applications.
• Databricks
  Core data–plus–AI platform that backs many of Lux’s AI–focused investments.

• 
  Thrive Capital

  BenchlingDatabricks
• 
  Andreessen Horowitz

  Databricks
• 
  Benchmark

  Benchling
• 
  Initialized Capital

  Runway
• 
  Insight Partners

  Databricks
• 
  Menlo Ventures

  Benchling